Rabacfosadine for relapsed canine B-cell lymphoma: Efficacy and adverse event profiles of 2 different doses

C. F. Saba, K. R. Vickery, C. A. Clifford, K. E. Burgess, B. Phillips, D. M. Vail, Z. M. Wright, M. A. Morges, Timothy M Fan, D. H. Thamm

Research output: Contribution to journalArticle

Abstract

Rabacfosadine (RAB), a novel double prodrug of the acyclic nucleotide phosphonate PMEG, preferentially targets neoplastic lymphocytes with reduced off target toxicity. Historical studies have suggested that every 21-day dosing is effective with acceptable toxicity. The purpose of this study was to evaluate RAB’s safety and efficacy at 2 different doses every 21 days in dogs with relapsed B-cell lymphoma. Dogs that had failed 1 doxorubicin-based chemotherapy protocol were eligible for inclusion in this prospective trial. Once enrolled, dogs were randomized to receive RAB at either 0.82 mg/kg or 1.0 mg/kg as a 30-minute IV infusion every 21 days for up to 5 treatments. Response assessment and adverse event (AE) evaluation were performed every 21 days via VCOG criteria. Fifty dogs were enrolled, with 16 treated at 0.82 mg/kg and 34 treated at 1.0 mg/kg. The overall response rate was 74%, with 45% of dogs experiencing a complete response (CR). The median progression free intervals (PFIs) were 108 days, 172 days and 203 days for all dogs, all responders, and all CRs, respectively. Response rates and PFIs were similar in both treatment groups. The incidence of AEs, dose delays, dose reductions and withdrawals were not statistically different between the 2 groups. The AEs observed were similar to those previously reported and included hematologic, gastrointestinal, dermatologic and pulmonary AEs. One dog had grade 5 pulmonary fibrosis; otherwise, AEs resolved with supportive treatment. Rabacfosadine is a generally well tolerated, effective chemotherapy option for dogs with relapsed B-cell lymphoma.

Original languageEnglish (US)
Pages (from-to)E76-E82
JournalVeterinary and comparative oncology
Volume16
Issue number1
DOIs
StatePublished - Mar 2018

Fingerprint

B-Cell Lymphoma
lymphoma
B-lymphocytes
Canidae
Dogs
dogs
dosage
drug therapy
lungs
toxicity
phosphonates
Drug Therapy
Organophosphonates
doxorubicin
Pulmonary Fibrosis
Prodrugs
fibrosis
Doxorubicin
lymphocytes
Therapeutics

Keywords

  • chemotherapy
  • dogs
  • lymphoma
  • relapsed
  • resistant

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Saba, C. F., Vickery, K. R., Clifford, C. A., Burgess, K. E., Phillips, B., Vail, D. M., ... Thamm, D. H. (2018). Rabacfosadine for relapsed canine B-cell lymphoma: Efficacy and adverse event profiles of 2 different doses. Veterinary and comparative oncology, 16(1), E76-E82. https://doi.org/10.1111/vco.12337

Rabacfosadine for relapsed canine B-cell lymphoma : Efficacy and adverse event profiles of 2 different doses. / Saba, C. F.; Vickery, K. R.; Clifford, C. A.; Burgess, K. E.; Phillips, B.; Vail, D. M.; Wright, Z. M.; Morges, M. A.; Fan, Timothy M; Thamm, D. H.

In: Veterinary and comparative oncology, Vol. 16, No. 1, 03.2018, p. E76-E82.

Research output: Contribution to journalArticle

Saba, CF, Vickery, KR, Clifford, CA, Burgess, KE, Phillips, B, Vail, DM, Wright, ZM, Morges, MA, Fan, TM & Thamm, DH 2018, 'Rabacfosadine for relapsed canine B-cell lymphoma: Efficacy and adverse event profiles of 2 different doses', Veterinary and comparative oncology, vol. 16, no. 1, pp. E76-E82. https://doi.org/10.1111/vco.12337
Saba, C. F. ; Vickery, K. R. ; Clifford, C. A. ; Burgess, K. E. ; Phillips, B. ; Vail, D. M. ; Wright, Z. M. ; Morges, M. A. ; Fan, Timothy M ; Thamm, D. H. / Rabacfosadine for relapsed canine B-cell lymphoma : Efficacy and adverse event profiles of 2 different doses. In: Veterinary and comparative oncology. 2018 ; Vol. 16, No. 1. pp. E76-E82.
@article{a1ce22c4acef450ca6bdce5bd294035b,
title = "Rabacfosadine for relapsed canine B-cell lymphoma: Efficacy and adverse event profiles of 2 different doses",
abstract = "Rabacfosadine (RAB), a novel double prodrug of the acyclic nucleotide phosphonate PMEG, preferentially targets neoplastic lymphocytes with reduced off target toxicity. Historical studies have suggested that every 21-day dosing is effective with acceptable toxicity. The purpose of this study was to evaluate RAB’s safety and efficacy at 2 different doses every 21 days in dogs with relapsed B-cell lymphoma. Dogs that had failed 1 doxorubicin-based chemotherapy protocol were eligible for inclusion in this prospective trial. Once enrolled, dogs were randomized to receive RAB at either 0.82 mg/kg or 1.0 mg/kg as a 30-minute IV infusion every 21 days for up to 5 treatments. Response assessment and adverse event (AE) evaluation were performed every 21 days via VCOG criteria. Fifty dogs were enrolled, with 16 treated at 0.82 mg/kg and 34 treated at 1.0 mg/kg. The overall response rate was 74{\%}, with 45{\%} of dogs experiencing a complete response (CR). The median progression free intervals (PFIs) were 108 days, 172 days and 203 days for all dogs, all responders, and all CRs, respectively. Response rates and PFIs were similar in both treatment groups. The incidence of AEs, dose delays, dose reductions and withdrawals were not statistically different between the 2 groups. The AEs observed were similar to those previously reported and included hematologic, gastrointestinal, dermatologic and pulmonary AEs. One dog had grade 5 pulmonary fibrosis; otherwise, AEs resolved with supportive treatment. Rabacfosadine is a generally well tolerated, effective chemotherapy option for dogs with relapsed B-cell lymphoma.",
keywords = "chemotherapy, dogs, lymphoma, relapsed, resistant",
author = "Saba, {C. F.} and Vickery, {K. R.} and Clifford, {C. A.} and Burgess, {K. E.} and B. Phillips and Vail, {D. M.} and Wright, {Z. M.} and Morges, {M. A.} and Fan, {Timothy M} and Thamm, {D. H.}",
year = "2018",
month = "3",
doi = "10.1111/vco.12337",
language = "English (US)",
volume = "16",
pages = "E76--E82",
journal = "Veterinary and Comparative Oncology",
issn = "1476-5829",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Rabacfosadine for relapsed canine B-cell lymphoma

T2 - Efficacy and adverse event profiles of 2 different doses

AU - Saba, C. F.

AU - Vickery, K. R.

AU - Clifford, C. A.

AU - Burgess, K. E.

AU - Phillips, B.

AU - Vail, D. M.

AU - Wright, Z. M.

AU - Morges, M. A.

AU - Fan, Timothy M

AU - Thamm, D. H.

PY - 2018/3

Y1 - 2018/3

N2 - Rabacfosadine (RAB), a novel double prodrug of the acyclic nucleotide phosphonate PMEG, preferentially targets neoplastic lymphocytes with reduced off target toxicity. Historical studies have suggested that every 21-day dosing is effective with acceptable toxicity. The purpose of this study was to evaluate RAB’s safety and efficacy at 2 different doses every 21 days in dogs with relapsed B-cell lymphoma. Dogs that had failed 1 doxorubicin-based chemotherapy protocol were eligible for inclusion in this prospective trial. Once enrolled, dogs were randomized to receive RAB at either 0.82 mg/kg or 1.0 mg/kg as a 30-minute IV infusion every 21 days for up to 5 treatments. Response assessment and adverse event (AE) evaluation were performed every 21 days via VCOG criteria. Fifty dogs were enrolled, with 16 treated at 0.82 mg/kg and 34 treated at 1.0 mg/kg. The overall response rate was 74%, with 45% of dogs experiencing a complete response (CR). The median progression free intervals (PFIs) were 108 days, 172 days and 203 days for all dogs, all responders, and all CRs, respectively. Response rates and PFIs were similar in both treatment groups. The incidence of AEs, dose delays, dose reductions and withdrawals were not statistically different between the 2 groups. The AEs observed were similar to those previously reported and included hematologic, gastrointestinal, dermatologic and pulmonary AEs. One dog had grade 5 pulmonary fibrosis; otherwise, AEs resolved with supportive treatment. Rabacfosadine is a generally well tolerated, effective chemotherapy option for dogs with relapsed B-cell lymphoma.

AB - Rabacfosadine (RAB), a novel double prodrug of the acyclic nucleotide phosphonate PMEG, preferentially targets neoplastic lymphocytes with reduced off target toxicity. Historical studies have suggested that every 21-day dosing is effective with acceptable toxicity. The purpose of this study was to evaluate RAB’s safety and efficacy at 2 different doses every 21 days in dogs with relapsed B-cell lymphoma. Dogs that had failed 1 doxorubicin-based chemotherapy protocol were eligible for inclusion in this prospective trial. Once enrolled, dogs were randomized to receive RAB at either 0.82 mg/kg or 1.0 mg/kg as a 30-minute IV infusion every 21 days for up to 5 treatments. Response assessment and adverse event (AE) evaluation were performed every 21 days via VCOG criteria. Fifty dogs were enrolled, with 16 treated at 0.82 mg/kg and 34 treated at 1.0 mg/kg. The overall response rate was 74%, with 45% of dogs experiencing a complete response (CR). The median progression free intervals (PFIs) were 108 days, 172 days and 203 days for all dogs, all responders, and all CRs, respectively. Response rates and PFIs were similar in both treatment groups. The incidence of AEs, dose delays, dose reductions and withdrawals were not statistically different between the 2 groups. The AEs observed were similar to those previously reported and included hematologic, gastrointestinal, dermatologic and pulmonary AEs. One dog had grade 5 pulmonary fibrosis; otherwise, AEs resolved with supportive treatment. Rabacfosadine is a generally well tolerated, effective chemotherapy option for dogs with relapsed B-cell lymphoma.

KW - chemotherapy

KW - dogs

KW - lymphoma

KW - relapsed

KW - resistant

UR - http://www.scopus.com/inward/record.url?scp=85029208346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029208346&partnerID=8YFLogxK

U2 - 10.1111/vco.12337

DO - 10.1111/vco.12337

M3 - Article

C2 - 28891260

AN - SCOPUS:85029208346

VL - 16

SP - E76-E82

JO - Veterinary and Comparative Oncology

JF - Veterinary and Comparative Oncology

SN - 1476-5829

IS - 1

ER -